Earnings summaries and quarterly performance for Design Therapeutics.
Executive leadership at Design Therapeutics.
Board of directors at Design Therapeutics.
Research analysts covering Design Therapeutics.
Recent press releases and 8-K filings for DSGN.
Design Therapeutics Provides Clinical Development and Financial Updates
DSGN
New Projects/Investments
Guidance Update
- Design Therapeutics is actively engaged in clinical development for Friedreich ataxia (FA), myotonic dystrophy (DM1), and Fuchs corneal dystrophy, alongside a preclinical program for Huntington's disease.
- The company anticipates releasing multiple-dose data in the second half of 2026 for its FA program (DT-216P2), which aims to increase endogenous Frataxin levels.
- For its DM1 program, Design Therapeutics expects to initiate multiple dose studies in patients in the first half of 2026, with data projected for 2027.
- A Phase 2 biomarker study for the Fuchs corneal dystrophy program is expected to yield data in the second half of 2026.
- Design Therapeutics reported a strong cash position of over $200 million at the end of the last quarter, providing a financial runway into 2029.
Dec 4, 2025, 3:00 PM
Design Therapeutics Provides Clinical Development and Financial Update
DSGN
New Projects/Investments
Guidance Update
- Design Therapeutics (DSGN) is in clinical development for three major monogenic diseases: Friedreich ataxia (FA), Fuchs corneal dystrophy, and myotonic dystrophy type 1 (DM1), with a preclinical program in Huntington's.
- For its FA program, the company expects to have data from a multiple-dose trial in patients with DT-216P2 in the second half of 2026, following an improved formulation that demonstrated an over 10x increase in exposure and resolved prior safety issues.
- The Fuchs corneal dystrophy program anticipates Phase 2 biomarker study data in the second half of 2026, and the DM1 program is slated to begin multiple dose studies in patients in the first half of 2026, with data expected in 2027.
- Design Therapeutics maintains a strong financial position, ending the last quarter with over $200 million in cash, providing a runway into 2029.
Dec 4, 2025, 3:00 PM
Design Therapeutics Provides Updates on DM1, FA, and Fuchs Clinical Programs and Financial Position
DSGN
New Projects/Investments
Guidance Update
- Design Therapeutics announced that its DT-818 program for Myotonic Dystrophy Type 1 (DM1) will enter clinical studies in the first half of 2026, with initial splicing correction data expected in 2027. Preclinical data showed over 90% reduction of mutant RNA foci in a relevant model system.
- The company reported that the clinical hold has been lifted for its DT-216P2 program for Friedreich's Ataxia (FA), and the RESTOR-FA multiple ascending dose study is ongoing, with data expected in the back half of 2026. This study aims to understand the effect of DT-216P2 on increasing endogenous frataxin expression.
- Phase 2 data for DT-168, an eye drop for Fuchs endothelial corneal dystrophy, is anticipated in the back half of 2026 from a biomarker study designed to confirm the mechanism of action in corneal tissue.
- Design Therapeutics reported a strong financial position, closing the last quarter with over $200 million in cash, providing a runway into 2029.
Dec 3, 2025, 8:30 PM
Design Therapeutics Provides Updates on Clinical Programs and Financial Outlook
DSGN
New Projects/Investments
Guidance Update
- Design Therapeutics announced regulatory clearance for DT-818, its DM1 program, which is expected to enter the clinic in the first half of 2026 with initial splicing correction data anticipated in 2027.
- The company reported that the clinical hold for its DT-216P2 program for Friedreich's Ataxia (FA) has been lifted, and the RESTOR-FA study is ongoing, with data expected in the back half of 2026.
- Phase 2 data for DT-168, an eye drop for Fuchs endothelial corneal dystrophy, is also expected in the back half of 2026 from a biomarker study.
- Design Therapeutics closed the last quarter with over $200 million in cash, providing a runway into 2029.
Dec 3, 2025, 8:30 PM
Design Therapeutics Provides Updates on Clinical Programs and Financial Outlook
DSGN
New Projects/Investments
Guidance Update
- Design Therapeutics announced that DT-818 for Myotonic Dystrophy Type 1 (DM1) received regulatory clearance outside the U.S. and is expected to enter clinical studies in the first half of 2026. Preclinical models showed over 90% reduction of toxic RNA with DT-818 treatment.
- The clinical hold for DT-216P2 for Friedreich's Ataxia (FA) has been lifted. The RESTOR-FA multiple ascending dose study is ongoing, with data on increasing endogenous frataxin expression expected in the second half of 2026.
- The company anticipates Phase 2 data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) in the second half of 2026.
- Design Therapeutics reported a cash balance of over $200 million at the close of the last quarter, providing a cash runway into 2029.
Dec 3, 2025, 8:30 PM
Design Therapeutics Announces Plans for DT-818 Dosing and Reports Q3 2025 Financial Results
DSGN
Earnings
New Projects/Investments
- Design Therapeutics plans to initiate patient dosing of DT-818 for Myotonic Dystrophy Type-1 (DM1) in the first half of 2026.
- For the third quarter ended September 30, 2025, the company reported research and development expenses of $14.6 million, general and administrative expenses of $4.7 million, and a net loss of $17.0 million.
- As of September 30, 2025, Design Therapeutics held $206.0 million in cash, cash equivalents, and investment securities.
- The company anticipates data readouts in the second half of 2026 for its DT-216P2 trial in Friedreich Ataxia and its DT-168 trial in Fuchs Endothelial Corneal Dystrophy.
Nov 5, 2025, 9:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more